MedTrace Logo

Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance

NCT01445236 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-12-20

No results posted yet for this study

Summary

Immunosuppressive drugs can be successfully withdrawn in a fraction of liver transplant patients. Specific peripheral blood gene expression markers can be employed to select patients with a high likelihood of being tolerant. In the current study the investigators propose to conduct a pilot non-randomized prospective study in which gradual weaning of immunosuppressive drugs will be offered to liver recipients exhibiting a favorable peripheral blood gene expression profile.

Conditions

  • Liver Transplantation

Interventions

OTHER

Immunosuppresion withdrawal

Gradual discontinuation of all immunosuppressive drugs.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Alberto Sanchez-Fueyo, MD · Hospital Clinic of Barcelona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445236 on ClinicalTrials.gov